Matrix metalloproteinase-3 serum levels in schizophrenic patients-Reference-Cited by-同舟云学术

Matrix metalloproteinase-3 serum levels in schizophrenic patients

Published:2022-03-31 Issue: Volume: Page:1-7
ISSN:1365-1501
Container-title:International Journal of Psychiatry in Clinical Practice
language:en
Short-container-title:International Journal of Psychiatry in Clinical Practice

Author:

Ordak Michal¹^ORCID,Libman-Sokolowska Malgorzata²,Nasierowski Tadeusz²,Badyra Bogna³,Kaczmarek Leszek³,Muszynska Elzbieta⁴,Bujalska-Zadrozny Magdalena¹

Affiliation:

1. Department of Pharmacodynamics, Centre for Preclinical, Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland

2. Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland

3. Laboratory of Neurobiology, Nencki-EMBL Center of Excellence for Neural Plasticity and Brain Disorders: BRAINCITY, Nencki Institute of Experimental Biology of the Polish Academy of Sciences, Warsaw, Poland

4. Department of Medical Biology, Medical University of Bialystok, Bialystok, Poland

Publisher

Informa UK Limited

Subject

Psychiatry and Mental health

Link

https://www.tandfonline.com/doi/pdf/10.1080/13651501.2022.2057332

Reference38 articles.

1. Sex Differences in the Risk of Schizophrenia

2. Myelin Basic Protein synthesis is regulated by small non‐coding RNA 715

3. MMPs in learning and memory and neuropsychiatric disorders

4. Bio-Techne.com, USA R&D Systems, Inc. (2021). https://resources.rndsystems.com/pdfs/datasheets/dmp300.pdf?v=20211102&_ga=2.50851242.2006599157.1635757575-408740926.1584619107

5. Matrix Metalloprotease 3 Activity Supports Hippocampal EPSP-to-Spike Plasticity Following Patterned Neuronal Activity via the Regulation of NMDAR Function and Calcium Flux

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a fluorescence immunochromatography method for quantitative measurement of matrix metalloproteinase-9;Practical Laboratory Medicine;2024-01

2. An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present);Expert Opinion on Therapeutic Patents;2023-10-03

3. PECULIARITIES OF DYNAMICS OF INDICATORS OF PROTEINS OXIDATIVE MODIFICATION AND MATRIX METALLOPROTEINASE-9 ACTIVITY IN PATIENTS WITH PARANOID SCHIZOPHRENIA DEPENDING ON THE DISEASE DURATION;Wiadomości Lekarskie;2023